Toronto, Canada-based developers of MAPTUAL, an AI-powered commercial insights SaaS platform for pharmaceutical companies, Odaia raised USD 25 million in an oversubscribed Series B. The round took place on May 1, 2023. Threshold Ventures and Monograph Capital co-led the financing for the firm. Meanwhile, Wittington Ventures joined with the existing investors such as Flint Capital, BDC Capital’s Women in Technology Venture Fund, StandUp Ventures and Graphite Ventures.

As a part of the deal, Emily Melton, Managing Partner of Threshold Ventures and Charles Conn, co-founder and Partner of Monograph Ventures, intends to join ODAIA’s board. In addition, Megan Kelly, Principal of Threshold Ventures, also joins as a board observer.

Purpose of financing for Odaia

With the recent funding, ODAIA seeks to fuel expansion. It also has plans to support the rapid growth of its AI-powered solutions helping pharma companies put life-changing therapies in the hands of patients faster. 

What the company’s official has to say

Philip Poulidis, CEO and Co-Founder of ODAIA said, “Even in a challenging funding environment, our valued investors clearly recognized the significant problem we’re solving for the pharmaceutical industry. With these funds, we’ll continue to evolve our product and build out our team to ensure we’re able to offer our existing and future life science brands the predictive tools needed for today’s market and tomorrow’s. It’s our pleasure to welcome these investors to the ODAIA team.”

What the investors have to add

Emily Melton, Managing Partner at Threshold Ventures, further said, “ODAIA’s ability to constantly ingest and update a broad mix of life sciences data and turn it into comprehensive insights in near-real-time turns pharmaceutical sales from reactive to proactive. We’re thrilled to lead their Series B financing. ODAIA helps get life-changing drugs into the hands of those who need them faster and more efficiently.”

In addition, Charles Conn, Partner at Monograph Ventures, said, “ODAIA has built impressive AI solutions. They provide the pharmaceutical industry with the resources needed for the modern age. We’re confident that this latest round of funding will further empower their impressive team to quickly scale their offering, which will benefit those who rely on therapeutics for their health and wellbeing.”

About the company 

In 2018, Founders Helen Kontozopoulos and Philip Poulidis launched the company. The Canada-based company ODAIA is the leading provider of automated commercial predictive insights. Global life sciences organizations trust the company’s platform. 

ODAIA’s highly scalable as well as quick-to-deploy software-as-a-service platform, MAPTUAL, pharma sales reps can more efficiently engage with HCPs. In addition, sales managers can more effectively coach their teams, and marketers can gain a deep understanding of their market. They can also develop campaigns that deliver strong business results. 

For more extensive analysis and Market Intelligence reports, feel free to approach us.

We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know

if there are any discrepancies in any of our published stories,

-how we can improve,

-what stories you would like us to cover

–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!

Next Article

Previous articleUSA-based VMG Health acquires BSM Consulting for an undisclosed amount 
Next articleLos Angeles-based administration and management startup Essenvia raises USD 4 million in Pre Series A round
Jasleen Bhatia works as a content writer for VCBay News. She is pursuing her final semester in Bachelor of Business Administration from IIPS, DAVV. Driven by her keen interest in entrepreneurship and finance, she writes business-related articles.

LEAVE A REPLY

Please enter your comment!
Please enter your name here